Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy

Table 1 Comparison of baseline data between the two groups, n (%)

Characteristic	Experimental group (n = 60)	Control group (n = 50)	P value
Gender			1.000
Male	36 (60.00)	30 (60.00)
Female	24 (40.00)	20 (40.00)
Age (years)	62.23 ± 7.49	61.20 ± 7.74	0.480
Clinical stage			0.366
Stage III	8 (13.30)	4 (8.00)
Stage IV	52 (86.70)	46 (92.00)
Stage IV			0.532
Hepatic metastases	48 (80.00)	43 (86.00)
Bone metastases	3 (5.00)	1 (1.66)
Pulmonary metastasis	1 (1.66)	1 (1.66)
Brain metastases	0 (0.00)	1 (1.66)
Degree of differentiation			0.091
Low differentiation	30 (50.00)	35 (70.00)
Moderate differentiation	22 (36.70)	10 (20.00)
High differentiation	8 (13.30)	5 (10.00)
BMI (kg/m2)	20.58 ± 2.03	20.17 ± 1.65	0.256
Colon tumor	36 (60.00)	25 (50.00)	0.293
Rectal tumor	24 (40.00)	25 (50.00)

BMI: Body mass index.